JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital
Abstract
Aims: To investigate the incidence of acute endophthalmitis after intravitreal bevacizumab injections.
Methods: Patients who received treatment with intravitreal bevacizumab (1.25 mg/0.05 ml) injections for various indications between November 2020 and March 2022 were included in this retrospective study. The patients were followed up for 4 weeks after the injection in terms of acute endophthalmitis symptoms and signs.
Results: Acute endophthalmitis developed in 1 patient after 4593 intravitreal bevacizumab injections were administered to 1427 eyes of 1026 patients, and the incidence was found to be 0.0217%. The patient who developed acute endophthalmitis underwent pars plana vitrectomy and after 3 months, a significant improvement in visual acuity was observed.
Conclusion: Development of endophthalmitis postoperatively was found to be moderately low after intravitreal bevacizumab injection. It was concluded that following asepsis rules and optimal bevacizumab preparation conditions could further reduce this.

Keywords : Bevacizumab, intravitreal injections, endophthalmitis, complications

Download Article


1. Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®)in cancer treatment: a review of 15 years of clinical experience andfuture outlook. Cancer Treat Rev. 2020;86:102017.
2. Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in colorectalcancer: current role in treatment and the potential of biosimilars.Target Oncol. 2017;12(5):599-610.
3. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treatmyopic choroidal neovascularization: 2-year outcome. GraefesArch Clin Exp Ophthalmol. 2010;248(7):937-941.
4. Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitrealbevacizumab (Avastin) for age-related macular degeneration: acritical analysis of literature. Eye (Lond). 2010;24(5):816-824.
5. Badalà F. The treatment of branch retinal vein occlusion withbevacizumab. Curr Opin Ophthalmol. 2008;19(3):234-238.
6. Seo JW, Park IW. Intravitreal bevacizumab for treatment ofdiabetic macular edema. Korean J Ophthalmol. 2009;23(1):17-22.
7. Zayek M, Parker K, Rydzewska M, Rifai A, Bhat R, EyalF. Bevacizumab for retinopathy of prematurity: 2-yearneurodevelopmental follow-up. Am J Perinatol. 2021;38(11):1158-1166.
8. Xu Y, Tan CS. Safety and complications of intravitreal injectionsperformed in an Asian population in Singapore. Int Ophthalmol.2017;37(2):325-332.
9. Ahmed N, Rehman HU, Rafique M, Hamza MS, Mirza HA.Incidence of acute endophthalmitis after intravitreal bevacizumabinjection at a tertiary care hospital in Lahore. Cureus.2021;13(2):e13185.
10. Bro T, Derebecka M, Jørstad ØK, Grzybowski A. Off-label use ofbevacizumab for wet age-related macular degeneration in Europe.Graefes Arch Clin Exp Ophthalmol. 2020;258(3):503-511.
11. Durand ML. Endophthalmitis. Clin Microbiol Infect.2013;19(3):227-234.
12. Li T, Sun J, Min J, et al. Safety of receiving anti-vascularendothelial growth factor intravitreal injection in office-basedvs operating room settings: a meta-analysis. JAMA Ophthalmol.2021;139(10):1080-1088.
13. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, BahceciogluH. Incidence and management of acute endophthalmitis afterintravitreal bevacizumab (Avastin) injection. Eye (Lond).2009;23(12):2187-2193.
14. Karimi S, Fakhri N, Ansari I, Hassanpour K, Safi S. Incidence andmanagement of acute endophthalmitis after intravitreal injectionof bevacizumab. Int Ophthalmol. 2022;42(6):1827-1833.
15. Pradhan E, Duwal S, Bajimaya S, Thapa R, Sharma S, ManandharA. Acute endophthalmitis after intravitreal bevacizumabinjections at the tertiary centre in Nepal. Nepal J Ophthalmol.2018;10(19):107-110.
16. Falavarjani KG, Modarres M, Hashemi M, et al. Incidence ofacute endophthalmitis after intravitreal bevacizumab injection ina single clinical center. Retina. 2013;33(5):971-974.
17. Khan P, Khan L, Mondal P. Cluster endophthalmitis followingmultiple intravitreal bevacizumab injections from a single usevial. Indian J Ophthalmol. 2016;64(9):694-696.
18. Hébert M, You E, Hammamji K, et al. Impact of patient face maskuse on endophthalmitis after intravitreal anti-VEGF injections.Can J Ophthalmol. 2022;57(6):364-369.
19. Bavinger JC, Yu Y, VanderBeek BL. Comparative risk ofendophthalmitis after intravitreal injection with bevacizumab,aflibercept, and ranibizumab. Retina. 2019;39(10):2004-2011.
20. Tanaka K, Shimada H, Mori R, et al. Safety measures formaintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during theCOVID-19 pandemic. J Clin Med. 2022;11(3):876.
21. Sousa DC, Jalil A, Patton N, et al. Early pars plana vitrectomy inacute endophthalmitis: The Manchester Series. Ophthalmic SurgLasers Imaging Retina. 2022;53(2):96-102.
Article available in :
Volume 7, Issue 1, 2024
Page : 13-16
https://doi.org/10.32322/jhsm.1367325
Article Information
Received : 28 Eyl 2023
Accepted : 04 Kas 2023
Published : 15 Oca 2024
Corresponding Author :

Mustafa Berhuni: Department of Ophtalmology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkiye

[email protected]
Citation : Taşdemir Arı A, Berhuni M, Gürbostan Soysal G, Setge Tıskaoğlu N. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a tertiary hospital. J Health Sci Med. 2024;7(1):13-16.

Read: 186
Cited: 0
Download : 141
_Footer